# A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

> **NCT06682793** · PHASE1,PHASE2 · RECRUITING · sponsor: **A2 Biotherapeutics Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Colorectal Cancer
- Non-Small Cell Lung
- NSCLC (Non-small Cell Lung Cancer)
- Cancer
- Colon Cancer
- Rectal Cancer
- Lung Cancer
- CRC
- Head and Neck Squamous Cell Cancer
- HNSCC
- Renal Cell Carcinoma
- RCC
- Kidney Cancer
- Triple Negative Breast Cancer
- TNBC
- Colorectal Adenocarcinoma

## Interventions

- **BIOLOGICAL:** A2B395
- **DIAGNOSTIC_TEST:** xT CDx with HLA-LOH assay

## Key facts

- **NCT ID:** NCT06682793
- **Lead sponsor:** A2 Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2029-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06682793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06682793, "A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06682793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*